COMPANY PROFILE // THE 014 REPORT
Theriva Biologics, Inc.
TOVX (NYSE) · Formerly: Synthetic Biologics, Inc.; ADEONA PHARMACEUTICALS, INC.; PIPEX PHARMACEUTICALS, INC.; SHEFFIELD PHARMACEUTICALS INC; SHEFFIELD MEDICAL TECHNOLOGIES INC
Assembled from 1 government source in 2.7 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 26 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Theriva Biologics, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in NV, based in Rockville, MD; listed as TOVX (NYSE).[source] It has filed 43 documents with the SEC in the last 12 months; the latest is Form 8-K, filed 2026-11-20.[source] Every list and source checked for this page came back clear (26 of 26), dated in the checks panel.[source]
- red0
- amber0
- info0
- CLEAR26
- POSSIBLE MATCH0
- MATCH0
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- SHALLCROSS STEVEN A · CEO and CFO (Director,Officer) · latest Form 4 2026-01-06 · filing · LinkedIn search
- Kraws Jeffrey J · Director · latest Form 4 2026-01-06 · filing · LinkedIn search
- MONAHAN JOHN J · Director · latest Form 4 2026-01-06 · filing · LinkedIn search
- Wolf Jeffrey Alan · Director · latest Form 4 2026-01-06 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0000894158 | source |
| EIN | 13-3808303 | source |
| Business address (SEC) | 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MD, 20850 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-20 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-11-18 filing 8-K items 5.07 · SEC EDGAR
- 2026-11-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-11-02 filing 8-K items 1.01,2.01,7.01,9.01 · SEC EDGAR
- 2026-10-20 filing Proxy statement · SEC EDGAR
- 2026-10-09 filing PRE 14A · SEC EDGAR
- 2026-08-24 filing S-8 · SEC EDGAR
- 2026-08-11 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-11 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-06 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-08-04 officer change 8-K items 5.02,5.07,9.01 · SEC EDGAR
- 2026-07-07 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-06-29 filing Proxy statement · SEC EDGAR
- 2026-06-29 filing ARS · SEC EDGAR
- 2026-06-18 filing PRE 14A · SEC EDGAR
- 2026-06-11 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-06-05 filing 8-K items 8.01 · SEC EDGAR
- 2026-05-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-30 filing Proxy statement · SEC EDGAR
- 2026-04-20 filing PRE 14A · SEC EDGAR
- 2026-04-17 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-04-09 filing 8-K items 8.01 · SEC EDGAR
- 2026-03-23 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-03-16 filing Proxy statement · SEC EDGAR
- 2026-03-12 filing Annual report (10-K) · SEC EDGAR
- 2026-03-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-03-04 filing PRE 14A · SEC EDGAR
- 2026-02-18 filing 8-K items 1.01,7.01,9.01 · SEC EDGAR
170 earlier entries
- 2026-02-12 filing 8-K items 8.01
- 2026-01-12 filing 8-K items 8.01,9.01
- 2026-01-05 filing Proxy statement
- 2025-12-29 filing 8-K items 7.01,8.01,9.01
- 2025-12-23 filing PRE 14A
- 2025-12-15 filing 8-K items 8.01
- 2025-12-03 filing 424B5
- 2025-12-02 filing EFFECT
- 2025-12-01 filing CORRESP
- 2025-11-12 filing DEFA14A
- 2025-11-12 filing Quarterly report (10-Q)
- 2025-11-12 filing 8-K items 2.02,9.01
- 2025-11-10 filing Proxy statement
- 2025-11-07 filing S-3
- 2025-10-31 filing PRE 14A
- 2025-10-29 filing 8-K items 8.01,9.01
- 2025-10-29 filing 424B5
- 2025-10-24 filing 8-K items 8.01,9.01
- 2025-10-24 filing 424B5
- 2025-10-24 filing D
- 2025-10-20 filing 8-K items 8.01,9.01
- 2025-10-17 filing 8-K items 1.01,3.02,8.01,9.01
- 2025-10-16 filing 424B5
- 2025-10-16 filing 424B5
- 2025-10-16 filing 424B5
- 2025-10-16 filing 424B5
- 2025-10-14 filing 8-K items 7.01,8.01,9.01
- 2025-10-08 filing 8-K items 8.01,9.01
- 2025-10-06 filing S-8
- 2025-10-06 filing 8-K items 7.01,8.01,9.01
- 2025-10-02 filing 8-K items 2.05
- 2025-09-04 officer change 8-K items 5.02,5.07,9.01
- 2025-08-11 filing Quarterly report (10-Q)
- 2025-08-11 filing 8-K items 2.02,9.01
- 2025-07-09 filing ARS
- 2025-07-09 filing Proxy statement
- 2025-06-25 filing 8-K items 8.01
- 2025-06-20 filing 8-K items 8.01,9.01
- 2025-06-20 filing 424B5
- 2025-06-02 filing 8-K items 7.01,8.01,9.01
- 2025-05-14 filing Quarterly report (10-Q)
- 2025-05-14 filing 8-K items 2.02,9.01
- 2025-05-08 filing 8-K items 1.01,8.01,9.01
- 2025-05-08 filing 424B5
- 2025-05-07 filing EFFECT
- 2025-05-07 filing 8-K items 7.01,8.01,9.01
- 2025-05-05 filing CORRESP
- 2025-05-05 filing CORRESP
- 2025-05-01 insider First Form 3/4/5 on record for SHALLCROSS STEVEN A (CEO and CFO)
- 2025-05-01 insider First Form 3/4/5 on record for Kraws Jeffrey J (Director)
- 2025-05-01 insider First Form 3/4/5 on record for MONAHAN JOHN J (Director)
- 2025-05-01 insider First Form 3/4/5 on record for Wolf Jeffrey Alan (Director)
- 2025-03-31 filing 8-K items 7.01,8.01,9.01
- 2025-03-21 filing S-1/A
- 2025-03-06 filing Annual report (10-K)
- 2025-03-06 filing 8-K items 2.02,9.01
- 2025-01-23 filing CORRESP
- 2025-01-23 filing CORRESP
- 2025-01-21 filing CORRESP
- 2025-01-21 filing CORRESP
- 2025-01-21 filing S-1/A
- 2024-12-16 filing UPLOAD
- 2024-12-10 filing Registration (S-1)
- 2024-12-05 filing 8-K items 7.01,8.01,9.01
- 2024-11-20 filing S-8
- 2024-11-12 filing Quarterly report (10-Q)
- 2024-11-12 filing 8-K items 2.02,9.01
- 2024-11-01 officer change 8-K items 5.02,5.03,5.07,9.01
- 2024-10-16 filing 8-K items 7.01,8.01,9.01
- 2024-10-03 filing 8-K items 7.01,8.01,9.01
- 2024-10-01 filing ARS
- 2024-09-30 filing Proxy statement
- 2024-09-30 filing 8-K items 1.01,8.01,9.01
- 2024-09-27 filing 424B5
- 2024-09-26 filing 424B5
- 2024-09-25 filing EFFECT
- 2024-09-25 filing EFFECT
- 2024-09-23 filing CORRESP
- 2024-09-23 filing S-1/A
- 2024-09-23 filing 8-K items 7.01,8.01,9.01
- 2024-09-20 filing CORRESP
- 2024-09-18 filing PRE 14A
- 2024-09-16 filing UPLOAD
- 2024-09-16 filing 8-K items 2.03,7.01,8.01,9.01
- 2024-09-11 filing S-3/A
- 2024-09-10 filing Registration (S-1)
- 2024-09-09 filing 8-K items 8.01
- 2024-08-26 filing 8-K items 3.03,5.03,9.01
- 2024-08-16 filing 8-K items 3.03,5.03,8.01,9.01
- 2024-08-13 filing Quarterly report (10-Q)
- 2024-08-13 filing 8-K items 2.02,9.01
- 2024-07-31 filing 8-K items 7.01,8.01,9.01
- 2024-05-23 filing 8-K items 7.01,8.01,9.01
- 2024-05-16 filing 8-K items 8.01
- 2024-05-08 filing UPLOAD
- 2024-05-07 filing Quarterly report (10-Q)
- 2024-05-07 filing 8-K items 2.02,9.01
- 2024-05-02 filing S-3
- 2024-05-02 filing 8-K items 1.01,9.01
- 2024-04-23 filing 8-K items 7.01,8.01,9.01
- 2024-04-22 filing 8-K items 7.01,8.01,9.01
- 2024-04-16 filing 8-K items 7.01,9.01
- 2024-03-25 filing Annual report (10-K)
- 2024-03-25 filing 8-K items 2.02,9.01
- 2024-02-07 filing 8-K items 7.01,8.01,9.01
- 2024-01-08 filing 8-K items 7.01,9.01
- 2023-11-13 filing Quarterly report (10-Q)
- 2023-11-13 filing 8-K items 2.02,9.01
- 2023-10-23 filing 8-K items 7.01,8.01,9.01
- 2023-10-17 filing 8-K items 7.01,8.01,9.01
- 2023-10-03 filing 8-K items 5.07,9.01
- 2023-08-16 filing DEFR14A
- 2023-08-15 filing ARS
- 2023-08-14 filing Proxy statement
- 2023-08-11 filing 8-K items 5.03,9.01
- 2023-08-08 filing Quarterly report (10-Q)
- 2023-08-08 filing 8-K items 2.02,9.01
- 2023-08-02 filing 8-K items 7.01,8.01,9.01
- 2023-06-27 filing 8-K items 7.01,8.01,9.01
- 2023-05-11 filing Quarterly report (10-Q)
- 2023-05-11 filing 8-K items 2.02,9.01
- 2023-03-30 filing Annual report (10-K)
- 2023-03-30 filing 8-K items 2.02,9.01
- 2023-03-10 filing 8-K items 4.02,8.01,9.01
- 2023-02-16 filing 8-K items 7.01,8.01,9.01
- 2023-01-17 filing 8-K items 7.01,8.01,9.01
- 2023-01-09 filing 8-K items 7.01,8.01,9.01
- 2022-12-23 filing 8-K items 1.01,9.01
- 2022-12-20 officer change 8-K items 5.02,9.01
- 2022-12-08 filing EFFECT
- 2022-12-05 filing 424B5
- 2022-12-05 filing POS AM
- 2022-11-10 filing 8-K items 2.02,9.01
- 2022-11-10 filing Quarterly report (10-Q)
- 2022-10-17 filing S-8
- 2022-10-12 filing 8-K items 5.03,7.01,8.01,9.01
- 2022-10-12 name change Name changed from Synthetic Biologics, Inc.
- 2022-10-03 officer change 8-K items 5.02,5.07,9.01
- 2022-09-30 filing 8-K items 7.01,8.01,9.01
- 2022-09-27 filing 8-K items 7.01,8.01,9.01
- 2022-09-16 filing 424B3
- 2022-09-14 filing EFFECT
- 2022-09-12 filing CORRESP
- 2022-09-12 filing 8-K items 8.01,9.01
- 2022-09-09 filing UPLOAD
- 2022-09-06 filing S-3
- 2022-09-06 filing 8-K/A items 9.01
- 2022-09-06 filing 8-K items 7.01,8.01,9.01
- 2022-08-16 filing Proxy statement
- 2022-08-11 filing DEFA14A
- 2022-08-11 filing Quarterly report (10-Q)
- 2022-08-11 filing 8-K items 2.02,9.01
- 2022-08-04 filing D
- 2022-08-03 filing PRE 14A
- 2022-08-03 filing 8-K items 3.03,9.01
- 2022-08-01 filing DEFA14A
- 2022-07-29 filing 8-K items 1.01,3.02,3.03,5.03,8.01,9.01
- 2022-07-25 filing 8-K items 3.03,5.03,9.01
- 2022-07-15 filing 8-K items 3.03,5.03,8.01,9.01
- 2022-07-14 filing 8-K items 8.01,9.01
- 2022-05-16 filing 8-K items 7.01,8.01,9.01
- 2022-05-16 filing Quarterly report (10-Q)
- 2022-05-16 filing 8-K items 2.02,9.01
- 2022-05-10 filing 8-K items 7.01,8.01,9.01
- 2022-05-06 filing 8-K/A items 2.01,9.01
- 2022-03-23 officer change 8-K items 5.02,7.01,9.01
- 2022-03-21 filing D
- 2022-03-16 filing Annual report (10-K)
- 2022-03-16 filing 8-K items 2.02,9.01
- 2022-03-11 filing 8-K items 1.01,2.01,3.02,7.01,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-20 (within 7 days) 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-11-18 (within 7 days) 8-K filed: Item 5.07 shareholder vote
- 2026-11-12 (within 30 days) 10-Q filed
- 2026-11-12 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-02 (within 30 days) 8-K filed: Item 1.01 material agreement; Item 2.01 acquisition or disposition; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-20 (older) DEF 14A filed
- 2026-10-09 (older) PRE 14A filed
- 2026-08-24 (older) S-8 filed (FORM S-8)
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NYSE:TOVX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
1 possible match held apart, matched by name only, not counted above; 7 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 894158 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | TOVX / NYSE | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 133808303 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000894158 | SEC EDGAR / IRS |
former name (shown apart, not merged) (7)
- former nameSheffield Pharmaceuticals · DOJ and agency corporate enforcement
- former nameSHEFFIELD PHARMACEUTICALS, LLC · Connecticut business registrations
- former nameSHEFFIELD PHARMACEUTICALS, LLC · Connecticut business registrations
- former nameSHEFFIELD PHARMACEUTICALS, LLC · State licences
- former nameSHEFFIELD PHARMACEUTICALS LLC · State spending
- former nameSHEFFIELD PHARMACEUTICALS · EPA ECHO facilities
- former nameSHEFFIELD PHARMACEUTICALS LLC · EPA ECHO facilities
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$23,739,000 | 2025-12-31 | 10-K, XBRL ProfitLoss | as filed | 2026-11-22 09:59 UTC | Report an error |
| Total assets (at 2025-12-31) | $38,239,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 09:59 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $15,383,000 | 2025-12-31 | 10-K, XBRL StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | as filed | 2026-11-22 09:59 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $13,056,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 09:59 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-22 09:59 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-22 09:59 UTC | Report an error |
| State of incorporation | NV | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-22 09:59 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-22 09:59 UTC | Report an error |
| Business address | 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MD, 20850 | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-22 09:59 UTC | Report an error |
| Exchanges | NYSE | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-22 09:59 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$16,669,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 09:59 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $35,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-22 09:59 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $1,671,000 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-22 09:59 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $901,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 09:59 UTC | Report an error |
| Form D total offering amount (D filed 2025-10-24) | $13,109,494 | 2025-10-24 | D | as filed | 2026-11-22 09:59 UTC | Report an error |
| Form D total amount sold (D filed 2025-10-24) | $13,109,494 | 2025-10-24 | D | as filed | 2026-11-22 09:59 UTC | Report an error |
| Form D industry group | Biotechnology | 2025-10-24 | D | as filed | 2026-11-22 09:59 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2025-10-24 | D | as filed | 2026-11-22 09:59 UTC | Report an error |
| Form D date of first sale | 2025-10-17 | 2025-10-24 | D | as filed | 2026-11-22 09:59 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001104659-26-125918
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $300,000 | 9 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125918 | 2026-11-22 09:59 UTC | Report an error |
| Net income (loss) | -$1,471,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125918 | 2026-11-22 09:59 UTC | Report an error |
| Interest expense | $16,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125918 | 2026-11-22 09:59 UTC | Report an error |
| Cash and cash equivalents | $8,473,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125918 | 2026-11-22 09:59 UTC | Report an error |
| Debt due in the next 12 months | $34,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125918 | 2026-11-22 09:59 UTC | Report an error |
| Debt due in year 2 | $11,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125918 | 2026-11-22 09:59 UTC | Report an error |
| Debt due in year 3 | $129,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125918 | 2026-11-22 09:59 UTC | Report an error |
| Debt due in year 4 | $224,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125918 | 2026-11-22 09:59 UTC | Report an error |
| Debt due in year 5 | $233,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125918 | 2026-11-22 09:59 UTC | Report an error |
| Debt due after year 5 | $1,030,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125918 | 2026-11-22 09:59 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-20 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-11-18 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-11-12 Filing 10-Q filed
- 2026-11-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-02 Filing 8-K filed: Item 1.01 material agreement; Item 2.01 acquisition or disposition; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-20 Filing DEF 14A filed
- 2026-10-09 Filing PRE 14A filed
- 2026-08-24 Filing S-8 filed (FORM S-8)
- 2026-08-11 Filing 10-Q filed
- 2026-08-11 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-06 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-04 Filing 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-07-07 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-29 Filing DEF 14A filed
- 2026-06-29 Filing ARS filed
- 2026-06-18 Filing PRE 14A filed
- 2026-06-11 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-05 Filing 8-K filed: Item 8.01 other event
- 2026-05-05 Filing 10-Q filed
- 2026-05-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-30 Filing DEF 14A filed
- 2026-04-20 Filing PRE 14A filed
- 2026-04-17 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-04-09 Filing 8-K filed: Item 8.01 other event
- 2026-03-23 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-11-20 8-K Item 8.01, Other Events
On November 20, 2026, Theriva Biologics, Inc., a Nevada corporation (the “Company”), issued a press release announcing that the Company’s Board of Directors approved a 1-for-30 reverse stock split of the Company’s issued, outstanding and authorized common stock, pursuant to Section 78.207 of the Nevada Revised Statutes (the “Reverse Stock Split”). The Reverse Stock Split is anticipated to be effective as of 11:59 p.m. (Eastern Time) on December 1, 2026, and it is expected that the Company’s common stock will begin trading on a split-adjusted basis as of the open of trading on December 2, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by… the 8-K · retrieved 2026-11-22 09:59 UTC - 2026-11-18 8-K Item 5.07, Submission of Matters to a Vote of Security Holders
On November 18, 2026, Theriva Biologics, Inc. (the “Company”) held a special meeting of its stockholders (the “Special Meeting”), where the Company’s stockholders voted on the following three (3) proposals and cast their votes as described below. These matters are described in detail in the Company’s definitive proxy statement on Schedule 14A for the Special Meeting, which was filed with the Securities and Exchange Commission on October 20, 2026 (the “Definitive Proxy Statement”). As of October 9, 2026, the record date for the Special Meeting, 45,892,688 shares of the Company’s common stock were issued and outstanding, and 16,754,223 shares of common stock, or approximately 36.5% of the… the 8-K · retrieved 2026-11-22 09:59 UTC - 2026-11-12 8-K Item 2.02, Results of Operations and Financial
Condition. On November 12, 2026, Theriva Biologics, Inc., a Nevada corporation (the “Company”), issued a press release that included financial information for its quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The… the 8-K · retrieved 2026-11-22 09:59 UTC - 2026-11-02 8-K Item 1.01, Entry into a Material Definitive Agreement
On October 30, 2026 (the “Effective Date”), Theriva Biologics, Inc. (the “Company”) entered into an Asset Purchase and Sale Agreement (the “Purchase Agreement”) with Biossil Labs Inc., a corporation organized under the laws of Canada (the “Biossil”), pursuant to which the Company sold to Biossil, and Biossil purchased from the Company, the Company’s assets exclusively relating to SYN-004 (ribaxamase), the Company’s oral β-lactamase product candidate, including its improvements, modifications and reformulations, including SYN-007 (collectively, “Ribaxamase”), as well as certain assets exclusively related to SYN-006, the Company’s carbapenemase product candidate (collectively, the “Purchased… the 8-K · retrieved 2026-11-22 09:59 UTC - 2026-11-02 8-K Item 2.01, Completion of Acquisition or Disposition
of Assets. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. The Closing occurred on October 30, 2026. the 8-K · retrieved 2026-11-22 09:59 UTC - 2026-11-02 8-K Item 7.01, Regulation FD Disclosure
On November 2, 2026, the Company issued a press release announcing the Agreement, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any… the 8-K · retrieved 2026-11-22 09:59 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchTheriva Biologics, Inc. · exact legal name · sx:ctgov:h1d90ef8abb29fc06 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/894158.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0000894158. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.